Adrenomedullin's Clinical Promise: From Vasodilation to Sepsis Biomarker to Potential Drug
Adrenomedullin has transitioned from a laboratory curiosity to a clinically relevant peptide with roles as a sepsis biomarker, heart failure prognostic marker, and potential therapeutic agent for cardiovascular and renal diseases.
Quick Facts
What This Study Found
Adrenomedullin has clinical relevance as both a biomarker (predicting outcomes in sepsis, HF, ACS) and a potential therapeutic (improving hemodynamics, protecting kidneys, reducing inflammation) — a dual biomarker-therapy peptide.
Key Numbers
How They Did This
Comprehensive review of adrenomedullin clinical studies covering biomarker applications (sepsis, HF, ACS prognosis) and therapeutic trials (hemodynamic improvement, renal protection).
Why This Research Matters
AM is rare — a peptide that both MEASURES disease severity and TREATS the disease. This dual role streamlines clinical development from biomarker to therapy.
The Bigger Picture
The biomarker-to-therapy paradigm (measure it to predict disease, give it to treat disease) is exemplified by AM and natriuretic peptides. This approach accelerates clinical translation.
What This Study Doesn't Tell Us
Review from 2004. Clinical therapeutic trials were mostly small. The optimal therapeutic dose and formulation were not established.
Questions This Raises
- ?Will AM-based therapy achieve clinical approval?
- ?Can MR-proADM (the clinical biomarker) guide AM therapeutic dosing?
- ?Would AM infusion improve sepsis survival in a large trial?
Trust & Context
- Key Stat:
- Biomarker AND therapy AM measures disease severity (biomarker) and improves it when administered (therapy) — rare dual utility from a single peptide
- Evidence Grade:
- Strong evidence from a comprehensive review integrating biomarker and therapeutic clinical data.
- Study Age:
- Published in 2004. MR-proADM is now an established clinical sepsis biomarker, and AM-targeting therapy (adrecizumab) is in clinical trials.
- Original Title:
- The clinical relevance of adrenomedullin: a promising profile?
- Published In:
- Pharmacology & therapeutics, 103(3), 179-201 (2004)
- Authors:
- Bunton, David C, Petrie, Mark C(15), Hillier, Chris, Johnston, Fiona, McMurray, John J V
- Database ID:
- RPEP-00888
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Can adrenomedullin both predict and treat disease?
Yes — elevated AM levels predict poor outcomes in sepsis and heart failure (biomarker), and giving AM improves hemodynamics and protects kidneys (therapy). It's rare for one peptide to serve both roles.
Is AM testing available?
MR-proADM (a stable AM fragment) is clinically available as a sepsis biomarker. AM-targeting therapy is in clinical trials.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-00888APA
Bunton, David C; Petrie, Mark C; Hillier, Chris; Johnston, Fiona; McMurray, John J V. (2004). The clinical relevance of adrenomedullin: a promising profile?. Pharmacology & therapeutics, 103(3), 179-201.
MLA
Bunton, David C, et al. "The clinical relevance of adrenomedullin: a promising profile?." Pharmacology & therapeutics, 2004.
RethinkPeptides
RethinkPeptides Research Database. "The clinical relevance of adrenomedullin: a promising profil..." RPEP-00888. Retrieved from https://rethinkpeptides.com/research/bunton-2004-the-clinical-relevance-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.